A Trial of SHR7280 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-19

Study Completion Date

2025-07-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is being conducted to evaluate the effect of high-fat meal on pharmacokinetics of SHR7280 after oral administration and the effect of SHR7280 on QT interval at low and high doses in healthy Chinese volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

NCT04326881

Pharmacokinetic

UNKNOWN PHASE1

A Pharmacokinetic Study of SHR8554 Injection in the Population With Renal Insufficiency and Healthy Participants

NCT07189962

Moderate to Severe Postoperative Pain

COMPLETED PHASE1

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

NCT02663687

Hereditary Angioedema (HAE)

COMPLETED PHASE1

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

NCT04631549

Hepatic Impairment Healthy Participants

UNKNOWN PHASE1

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

NCT04667156

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometriosis Uterine Fibroids Assisted Reproduction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group A

Group Type EXPERIMENTAL

SHR7280 Tablet

Intervention Type DRUG

Oral SHR7280 tablet.

SHR7280 Placebo Tablet

Intervention Type DRUG

Oral SHR7280 placebo tablet.

Treatment group B

Group Type EXPERIMENTAL

SHR7280 Tablet

Intervention Type DRUG

Oral SHR7280 tablet.

SHR7280 Placebo Tablet

Intervention Type DRUG

Oral SHR7280 placebo tablet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SHR7280 Tablet

Oral SHR7280 tablet.

Intervention Type DRUG

SHR7280 Placebo Tablet

Oral SHR7280 placebo tablet.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntarily sign the informed consent form prior to any activities in the trail, demonstrate comprehension of the trial procedures and methodology, and agree to strictly adhere to the protocol throughout the study period.
2. Be aged between 18 and 45 years inclusive (determined at the time of signing the informed consent form).
3. Have a body weight of ≥50 kg for males and ≥45 kg for females, with a Body Mass Index (BMI) between 18 and 26 kg/m² inclusive.
4. Have no plans for pregnancy or sperm/egg donation from the time of signing the inform consent form until 1 week after the last administration of the investigational product, and agree to use highly effective contraceptive measures.

Exclusion Criteria

1. Individuals with a history of chronic or serious diseases, or current conditions affecting the respiratory, circulatory, digestive, urinary, hematological, endocrine, immune, nervous, or psychiatric systems, and deemed ineligible to participate in this trial by the investigator.
2. Females who are pregnant, breastfeeding, or with a positive serum pregnancy test during the screening or baseline period.
3. History of smoking (average daily cigarette consumption \>5 cigarettes) within 3 months prior to randomization, or any use of tobacco products during the study period.
4. History of drug abuse, positive urine drug abuse screen at the screening period.
5. Receipt of live (attenuated) vaccines within 1 month prior to screening or planned administration during the trial (excluding influenza vaccines).
6. Undergoing any surgical procedure within 3 months prior to randomization, incomplete recovery from surgery, or anticipated need for surgery or hospitalization during the trial period.
7. Inability to comply with standardized dietary requirements, intolerance to high-fat meals, or presence of dysphagia.
8. Any condition judged by the investigator to potentially affect drug absorption, distribution, metabolism, or excretion, reduce compliance, or pose other risks that make participation in the study inappropriate.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes